A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging
- 10 June 2021
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 188 (2) , 415-425
Abstract
Purpose Sorafenib has demonstrated anti-tumor efficacy and radiosensitizing activity preclinically and in breast cancer. We examined sorafenib in combination with whole brain radiotherapy (WBRT) and explored the [18F] 3′deoxy-3′-fluorothymidine (FLT)-PET as a novel brain imaging modality in breast cancer brain metastases. Methods A phase I trial of WBRT + sorafenib was conducted using a 3 + 3 design with safety-expansion cohort. Sorafenib was given daily at the start of WBRT for 21 days. The primary endpoints were to determine a maximum tolerated dose (MTD) and to evaluate safety and toxicity. The secondary endpoint was CNS progression-free survival (CNS-PFS). MacDonald Criteria were used for response assessment with a correlative serial FLT-PET imaging study. Results 13 pts were evaluable for dose-limiting toxicity (DLT). DLTs were grade 4 increased lipase at 200 mg (n = 1) and grade 3 rash at 400 mg (n = 3). The MTD was 200 mg. The overall response rate was 71%. Median CNS-PFS was 12.8 months (95%CI: 6.7-NR). A total of 15 pts (10 WBRT + sorafenib and 5 WBRT) were enrolled in the FLT-PET study: baseline (n = 15), 7–10 days post WBRT (FU1, n = 14), and an additional 12 week (n = 9). A decline in average SUVmax of ≥ 25% was seen in 9/10 (90%) of WBRT + sorafenib patients and 2/4 (50%) of WBRT only patients. Conclusions Concurrent WBRT and sorafenib appear safe at 200 mg daily dose with clinical activity. CNS response was favorable compared to historical controls. This combination should be considered for further efficacy evaluation. FLT-PET may be useful as an early response imaging tool for brain metastases. Trial and Clinical Registry Trial registration numbers and dates: NCT01724606 (November 12, 2012) and NCT01621906 (June 18, 2012).Keywords
Funding Information
- Bayer
- Susan G. Komen
- American Society of Clinical Oncology
This publication has 51 references indexed in Scilit:
- Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signalingBreast Cancer Research and Treatment, 2013
- The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expressionOncology Reports, 2013
- Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular CarcinomaYonsei Medical Journal, 2013
- Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer modelAnti-Cancer Drugs, 2012
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast CancerJournal of Clinical Oncology, 2012
- Phase I trial of sorafenib in patients with recurrent or progressive malignant gliomaNeuro-Oncology, 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Incidence of brain metastases in renal cell carcinoma treated with sorafenibAnnals of Oncology, 2010
- Pseudoprogression and pseudoresponse in the treatment of gliomasCurrent Opinion in Neurology, 2009
- Renal Cell Cancer Presented with Leptomeningeal Carcinomatosis Effectively Treated with SorafenibOncology Research and Treatment, 2007